Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICAFUNGIN IN SODIUM CHLORIDE 0.9% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses,Treatment of esophageal candidiasis,Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life is approximately 13-20 hours in adults; supports once-daily dosing. Half-life is prolonged in moderate-to-severe hepatic impairment (Child-Pugh B/C) but no dosage adjustment is required.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Micafungin is metabolized by arylsulfatase and catechol-O-methyltransferase (COMT) to the M1 metabolite, and further metabolized by CYP3A4 to M2; however, CYP3A4 plays a minor role. The drug is not a significant inhibitor or inducer of CYP enzymes.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily biliary/fecal (≈71% of administered dose recovered in feces as parent drug and metabolites); renal excretion accounts for ≈15% (urine: <1% as unchanged drug).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Highly protein-bound (≥99.8%), primarily to albumin; slight binding to α1-acid glycoprotein.
Low protein binding; 0–11% bound, primarily to albumin.
Volume of distribution at steady state (Vss) is approximately 0.2-0.3 L/kg in adults; indicates limited tissue distribution, primarily confined to plasma and interstitial fluid.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Only available as intravenous infusion; oral bioavailability is negligible (<0.1%) due to poor gastrointestinal absorption.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No dosage adjustment required for any degree of renal impairment.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
In moderate hepatic impairment (Child-Pugh B), reduce dose to 100 mg once daily; no data for severe impairment (Child-Pugh C). No adjustment for mild impairment.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
For invasive candidiasis: 2 mg/kg (max 100 mg) intravenously once daily for patients ≥40 kg; 2 mg/kg once daily for patients <40 kg. For esophageal candidiasis: 3 mg/kg (max 150 mg) once daily.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
No specific dose adjustment; use standard adult dosing based on renal and hepatic function.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
There is no FDA black box warning for micafungin.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions,Hepatic effects: elevations in liver enzymes, bilirubin, and rare cases of hepatic necrosis or hepatitis,Renal effects: elevations in serum creatinine and BUN,Hematologic effects: hemolytic anemia, leukopenia, thrombocytopenia,Injection site reactions: phlebitis, thrombophlebitis,Photosensitivity and risk of skin malignancies in patients with prolonged exposure
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to micafungin or any component of the formulation
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No known food interactions. Grapefruit and grapefruit juice do not interact with micafungin.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Micafungin is classified as FDA Pregnancy Category C. In animal studies, embryotoxicity and skeletal abnormalities were observed at doses 0.04 times the human dose. No adequate human studies exist. First trimester: Theoretical risk based on animal data; use only if benefit justifies risk. Second/third trimester: Limited data; may be used if clearly needed due to lack of alternative therapy.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Unknown if micafungin is excreted in human milk. Due to high molecular weight (ca. 1292 Da) and high protein binding (>99%), excretion is likely minimal. M/P ratio not determined. Caution advised; consider alternative therapy or temporarily discontinue breastfeeding during infusion.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may alter pharmacokinetics. However, specific dose adjustment guidelines are unavailable. Standard adult dosing (100-200 mg/day for invasive candidiasis) is typically used; monitor clinical response and serum drug levels if available.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Micafungin is an echinocandin antifungal that inhibits beta-(1,3)-D-glucan synthase. Administer IV only; do not bolus. Monitor hepatic function due to risk of elevated transaminases. Caution in patients with moderate to severe hepatic impairment (Child-Pugh B/C). Use with caution in patients with hypersensitivity to other echinocandins. May increase sirolimus and nifedipine levels; monitor levels. No renal dose adjustment needed. Do not mix with other drugs in same infusion line.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is given intravenously to treat serious fungal infections.,Report any signs of allergic reaction: rash, itching, difficulty breathing, swelling of face or throat.,Monitor for symptoms of liver problems: jaundice, dark urine, abdominal pain, unexplained fatigue.,Inform your doctor about all medications you take, including over-the-counter drugs and supplements.,You may have blood tests to monitor liver function during treatment.,Do not drive or operate heavy machinery if you experience dizziness or confusion.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Micafungin, an echinocandin antifungal, inhibits CYP3A4 and P-glycoprotein, thereby decreasing the hepatic and intestinal metabolism of Lercanidipine, a CYP3A4 substrate. This leads to increased plasma concentrations of Lercanidipine, potentially causing excessive vasodilation, hypotension, reflex tachycardia, and peripheral edema. In severe cases, this interaction may precipitate syncope, myocardial ischemia, or acute kidney injury due to hypoperfusion."
"Rifapentine, a potent inducer of hepatic CYP450 enzymes and drug transporters, paradoxically increases serum concentrations of micafungin, an echinocandin antifungal. This interaction is thought to occur via inhibition of micafungin's biliary excretion and possibly through competitive binding to plasma proteins, leading to reduced clearance and elevated trough levels. Clinically, this may increase the risk of micafungin-related hepatotoxicity and requires close monitoring of liver function and therapeutic drug monitoring if available."
"Micafungin, a potent inhibitor of CYP3A4 and a substrate of CYP3A4, may reduce the hepatic clearance of Perhexiline, a CYP3A4 substrate with a narrow therapeutic index. Co-administration can result in elevated serum concentrations of Perhexiline, increasing the risk of hepatotoxicity and peripheral neuropathy. This interaction is significant as it may lead to adverse outcomes including liver injury and neurological deficits."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICAFUNGIN IN SODIUM CHLORIDE 0.9% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
MICAFUNGIN IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICAFUNGIN IN SODIUM CHLORIDE 0.9% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICAFUNGIN IN SODIUM CHLORIDE 0.9% is: 100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICAFUNGIN IN SODIUM CHLORIDE 0.9% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICAFUNGIN IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Micafungin is classified as FDA Pregnancy Category C. In animal studies, embryotoxicity and skeletal abnormalities were observed at doses 0.04 times the human dose. No adequate hum. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.